EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy of pioglitazone in improving cognitive function among dementia patients- a prospective, double blind randomized controlled trial

Ian Osoro, Robert S. Wilson, M. G. Rajanandh

Aging Clinical and Experimental Research · 19.11.2026

DOI: 10.1007/s40520-026-03556-4 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Aging Clinical and Experimental Research, online erschienen am 19.11.2026. Verfasst von Ian Osoro und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SRM Institute of Science & Technology.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cognitive impairment can arise from multiple neurodegenerative, vascular, metabolic, and other causes. Insulin resistance and impaired cerebral energy metabolism have been implicated in cognitive dysfunction, providing a rationale for evaluating pioglitazone as a potentially transdiagnostic metabolic intervention. This trial did not require biomarker-confirmed Alzheimer’s disease (AD); therefore, it was designed to evaluate treatment effects in adults with clinically diagnosed dementia and cognitive impairment rather than to test an AD-specific intervention.

Methods

In this single-centre, double-blind trial, 113 adults aged 18–64 years with clinically diagnosed dementia and cognitive impairment (Montreal Cognitive Assessment [MoCA] score < 26) were randomized to pioglitazone 15 mg once daily plus background donepezil therapy or placebo plus background donepezil therapy. Dementia was diagnosed clinically by the study neurologist using Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Pioglitazone/placebo was administered for the first 6 months, followed by a 6-month post-treatment observation period. Primary outcomes were longitudinal changes in MoCA score, P300 event-related potential (ERP) latency, P300 amplitude, and plasma Aβ42/Aβ40 ratio, analysed using mixed-model repeated-measures analysis. Safety and quality of life were secondary outcomes.

Results

Mixed-model repeated-measures analysis showed no statistically significant between-group differences in MoCA score ( P = 0.07), P300 latency ( P = 0.300), P300 amplitude ( P = 0.71), or plasma Aβ42/Aβ40 ratio ( P = 1.00). A total of 32 adverse drug reactions were reported; 17 (34.0%) participants in the intervention arm and 15 (30.6%) in the control arm reported at least one adverse drug reaction, with no statistically significant overall between-group difference ( P = 0.82).

Conclusion

In adults with clinically diagnosed dementia and cognitive impairment of unconfirmed etiology, adjunctive pioglitazone did not produce a statistically significant improvement in cognitive performance over the 12-month study period. It also did not produce detectable between-group changes in the electrophysiological or exploratory plasma amyloid measures. Because AD pathology was not established with validated central or appropriately validated blood-based biomarkers, the findings should not be interpreted as evidence for or against a disease-modifying effect of pioglitazone in AD specifically. Clinical trial number CTRI2024/09/074281. Registered on 24/09/2024

Förderung

  • SRM Institute of Science & Technology

Zitieren

APA

Osoro, I., Wilson, R. S., & Rajanandh, M. G. (2026). Efficacy of pioglitazone in improving cognitive function among dementia patients- a prospective, double blind randomized controlled trial. Aging Clinical and Experimental Research. https://doi.org/10.1007/s40520-026-03556-4

Vancouver

Osoro I, Wilson RS, Rajanandh MG. Efficacy of pioglitazone in improving cognitive function among dementia patients- a prospective, double blind randomized controlled trial. Aging Clinical and Experimental Research. 2026. doi:10.1007/s40520-026-03556-4

BibTeX
@article{Osoro2026,
  author = {Osoro, Ian and Wilson, Robert S. and Rajanandh, M. G.},
  title = {Efficacy of pioglitazone in improving cognitive function among dementia patients- a prospective, double blind randomized controlled trial},
  journal = {Aging Clinical and Experimental Research},
  year = {2026},
  doi = {10.1007/s40520-026-03556-4}
}
Kostenlos starten →